EIM
INDP icon

Essex Investment Management’s Indaptus Therapeutics INDP Stock Holding History

Essex Investment Management’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-127
Closed -$1.23M – 482
2019
Q2 		$1.23M Sell
127
-38
-23% -$479K 0.17% 192
2019
Q1 		$2.71M Sell
165
-11
-6% -$193K 0.4% 66
2018
Q4 		$2.97M Buy
+176
New +$2.4M 0.47% 55

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Essex Investment Management's INDP Position: Q3 2019 in Review

Essex Investment Management sold out of Indaptus Therapeutics (INDP) in Q3 2019, closing a stake of 127 shares — an estimated $1.23M sold.

Essex Investment Management first reported a position in INDP in Q4 2018 and held it in 3 quarters. The position peaked at $2.97M in Q4 2018. 33 funds tracked by Wall St. Rank hold INDP as of Q3 2019.

  • Essex Investment Management reported no remaining Indaptus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Essex Investment Management sold 127 Indaptus Therapeutics shares in Q3 2019, an estimated $1.23M.
  • Essex Investment Management first reported a position in Indaptus Therapeutics in Q4 2018 and held it in 3 quarters.
  • Essex Investment Management's Indaptus Therapeutics position peaked at $2.97M in Q4 2018.
  • 33 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2019.

Based on Essex Investment Management's 13F filing for Q3 2019, filed 22 Oct 2019.